Pacira Pharma (PCRX) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.35, $0.20 better than the analyst estimate of $0.15. Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.44 million.
Pacira ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments (“cash”) of $164.4 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
- Vistra stock sinks ahead of earnings report
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
